Tunisia is in a position to manufacture a new variety of drugs to further reduce purchases from abroad especially since the industrial potential is available and the specialized workforce is ready to succeed, with incentives at all levels.
In this context, Director General of Manufacturing Industries, Fethi Sahlaoui said in a statement to AfricanManager ar that the draft charter of public-private partnership in pharmaceutical industries 2025 is of great importance in the revitalization of the Tunisian economy and the know-how of the country’s skills.
He added that this project aims to strengthen the competitiveness of pharmaceutical industries and ensure a qualitative leap in the sector in 5 years, by increasing its technological content and ensuring its positioning in the biotechnology sector.
The charter of public-private partnership in the pharmaceutical industry sector aims to stimulate competitiveness between the actors of the pharmaceutical industry.
The partnership project also aims to stimulate competitiveness between the actors of the pharmaceutical industry and increase exports of the sector to 40%, said the official.
He added that the charter is based on 5 axes, namely governance, increasing value added, strengthening research, improving infrastructure, marketing and training.
He also said that the Ministry of Health supports this sector that can earn more foreign exchange through exports to neighboring countries and even in Africa.
A battery of effective and encouraging measures!
The measures to encourage investment in this sector have borne fruit. Thanks to these measures, drug professionals and all those interested in this sector have been able to benefit from an exemption on the acquisition of raw materials and imported packaging products. They also pay a VAT of 6% instead of 18%.
In addition, products with two Tunisian marketing authorizations can be put out to national tender. Foreign investors can also own 100% of the capital of a structure and have full freedom to transfer funds. These measures taken by the State have helped develop the pharmaceutical infrastructure and increase the country’s needs.
Subsidiaries of multinationals have ever since set up in the country, while national entrepreneurs have also set up their own companies.
Today, there are 56 production units in Tunisia. 28 of them produce medicines for human use, 6 producers of medicines for animals, 22 units producing medical equipment of which half are exporting companies.
The country also has 35 research centers, over 600 units specializing in scientific research and some 150 laboratories. This massive investment has enabled the sector to withstand the depreciation of the national currency and the impacts of the revolution of 2011…